Aurobindo Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)
Aurobindo Pharma Ltd · Outcome · 05 Nov 2026, 1:23 am
Aurobindo Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 1,02,633 (+23.9% YoY | +12.2% QoQ) ■ EBITDA: 21,558 (+28.5% YoY | +14.6% QoQ) ■ EBITDA Margin (%): 21.0 (+75 bps YoY | +45 bps QoQ) ■ PAT: 11,261 (+32.7% YoY | +9.1% QoQ) ■ EPS (INR): 19.6 (+33.9% YoY | +9.6% QoQ)
Original exchange filing (PDF)
More announcements from Aurobindo Pharma Ltd
- Intimation of classification of US FDA inspection at Lannet Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. · 12 Nov 2026
- Submission of Earning Call Transcript for Q2FY27. · 11 Nov 2026
- Unit-2 of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company received Establishment Inspection Report from US FDA with classification as "Voluntary Action Indicated". · 11 Nov 2026
- Intimation of investors / analysts meet to be held on 17.11.2026. · 09 Nov 2026
- Intimation of investor / analysts meet to be held on 16.09.2026. · 09 Nov 2026
- Submission of Financial results for the Quarter and Half year ended September 30, 2026. · 05 Nov 2026
- Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027. · 05 Nov 2026
- Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company. · 05 Nov 2026
